Localized Renal Cell Carcinoma

KIM-1 Biomarker Analysis in IMmotion010: Adjuvant Atezolizumab for RCC at High Recurrence Risk
Laurence Albiges, MD, PhD, of Gustave Roussy Institute, breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial. Patients in this phase 3 trial had renal cell carcinoma, were at increased risk of recurrence after resection, and were randomized to adjuvant atezolizumab or placebo. ...
Advertisement

Latest News

Advertisement

Knowledge Hub Spotlight

Curated clinical content based on conditions, therapies, and technologies

Renal Cell Carcinoma
Renal Cell Carcinoma

Conference Coverage

Advertisement
Advertisement
Latest News